Impact of Metabolic Associated Steatotic Liver Disease on Antiviral Therapy Outcomes on Chronic Hepatitis B Patients Receiving Antiviral Therapy
Journal of Medical Virology · 2026-03 · 98 (3)
DOI: 10.1002/jmv.70864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 18.03.2026. Verfasst von Sheng-Jie Shiue und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, Fatty Liver. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aim Chronic hepatitis B (CHB) affects over 250 million people globally and is a major contributor to liver complications, including cirrhosis and hepatocellular carcinoma (HCC). Though antiviral therapies suppress HBV, the rising prevalence of metabolic‐associated steatotic liver disease (MASLD) poses new challenges. This study assessed how MASLD influences liver‐related outcomes, fibrosis progression, and survival in CHB patients undergoing nucleus(t)ide analogs (NAs) therapy, using large‐scale data and clinical cohort analysis.
Methods
A retrospective study using the TriNetX US Collaborative Network, CHB patients receiving long‐term NA therapy with undetectable serum HBV DNA and concomitant MASLD (CHB‐MASLD‐NA, n = 5600) were compared with those without MASLD (CHB‐non MASLD‐NA, n = 11 021), matched 1:1 by propensity scores ( n = 4761 each after matching). Primary outcomes included 10‐year incidence of HCC and cirrhosis, with survival assessed via Kaplan–Meier curves and hazard ratios (HRs) from Cox models. Separately, a clinical cohort of 64 CHB patients and 137 MASLD‐only patients was assessed for steatosis (controlled attenuation parameter, CAP) and fibrosis (liver stiffness).
Results
Analysis revealed that co‐existing MASLD significantly compromised clinical outcomes. CHB‐MASLD‐NA patients faced a substantially higher risk of developing cirrhosis or HCC (HR 1.75, 95% CI 1.53–2.00, p < 0.001) and demonstrated lower 10‐year survival rates (61.5% vs. 79.3%, p < 0.001) compared to the non‐MASLD group. These findings were corroborated by the clinical cohort, where CHB‐MASLD‐NA patients exhibited greater liver stiffness (9.85 vs. 4.95 kPa) and a higher prevalence of advanced fibrosis compared to CHB alone and MASLD‐only groups (28.0% vs. 14.3% and 4.4%). HBV DNA load was not a significant predictor of outcomes in this population (HR 1.00). Notably, as steatosis worsened, the pro‐inflammatory cytokine TNF‐α increased more sharply (3.73‐fold) than the antiviral cytokine IFN‐γ (2.13‐fold).
Conclusions
MASLD drives fibrosis and mortality in NA‐treated CHB patients, as metabolic inflammation overrides the benefits of viral suppression. Integrated management, combining antiviral therapy, metabolic intervention, and immune monitoring, is essential to accurately assess progression and improve long‐term prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
- Graduate Institute of Chemical Engineering, National Taipei University of Technology, Taipei, Taiwan.
- Graduate Institute of Biochemical and Biomedical Engineering, National Taipei University of Technology, Taipei, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taiwan Adventist Hospital, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
ORCID-Profile: Ming-Shun Wu
Zitieren
APA
Shiue, S. J., Ho, T. H., Lin, H. Y., Cheng, S. W., Wu, L. W., Chan, T. S., Chen, C. N., Cheng, C. L., Lee, Y. K., Yang, H. Y., Shiue, H. S., Leng, K. F., & Wu, M. S. (2026). Impact of Metabolic Associated Steatotic Liver Disease on Antiviral Therapy Outcomes on Chronic Hepatitis B Patients Receiving Antiviral Therapy. Journal of Medical Virology, 98(3). https://doi.org/10.1002/jmv.70864
Vancouver
Shiue SJ, Ho TH, Lin HY, Cheng SW, Wu LW, Chan TS, et al. Impact of Metabolic Associated Steatotic Liver Disease on Antiviral Therapy Outcomes on Chronic Hepatitis B Patients Receiving Antiviral Therapy. Journal of Medical Virology. 2026;98(3). doi:10.1002/jmv.70864
BibTeX
@article{Shiue2026,
author = {Shiue, Sheng-Jie and Ho, Tung-Han and Lin, Hsin-Yi and Cheng, Sheng-Wei and Wu, Li-Wei and Chan, Tze-Sian and Chen, Chun-Nan and Cheng, Chao-Ling and Lee, Yan Kang and Yang, Hsien-Yao and Shiue, Han-Shiang and Leng, Kuo-Feng and Wu, Ming-Shun},
title = {Impact of Metabolic Associated Steatotic Liver Disease on Antiviral Therapy Outcomes on Chronic Hepatitis B Patients Receiving Antiviral Therapy},
journal = {Journal of Medical Virology},
year = {2026},
volume = {98},
number = {3},
doi = {10.1002/jmv.70864}
}
EUVIMED